Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

THE NICKLES GROUP, LLC filed a Q3 report for UCB, INC. on October 16, 2025, reporting $60,000 in lobbying income.

Lobbying for UCB, INC. · Biopharmaceutical company

All filings by THE NICKLES GROUP, LLC · Everything UCB, INC. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 16, 2025
Income
$60,000
What the client paid this registrant for the period.
Client based in
Georgia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Medicare/Medicaid

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to access to home infusion, including H.R. 993, Joe Fiandra Access to Home infusion Act of 2025. H.R. 946/S.1862, ORPHAN Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Issues related to the Orphan Drug Tax Credit. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes.

Health Issues

Issues related to medication step therapy. S.864, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs. Issues related to pharmacy benefit management reforms.

Trade (domestic/foreign)

Issues related to tariffs.

 Bills named in this filing 5

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem